 오퍼게시판 |
|
|
제 목:
|
Vonoprazan Fumarate |
|
등록분류: |
Offer to Sell |
|
내용: |
CAS NO: 1260141-27-2
Additional_detail: Vonoprazan fumarate (Takecab), discovered and developed by Takeda and Otsuka, was approved by the PMDA of Japan in December 2014, and is indicated for the treatment of gastric ulcer, duodenal ulcer and reflux esophagitis.
Vonoprazan fumarate is an oral, newly synthesised potassium-competitive acid blocker (P-CAB) with antisecretory activity. It is also a proton pump inhibitor (PPI) reversibly inhibiting H+/K+, ATPase. It is mainly used in the treatment of acid-related diseases such as GERD and peptic ulcer disease.
|
연락처 |
| 담
당 자: |
Xie Wen Feng |
| 회사주소: |
16/F,Huicheng Comm,Complex,No839 XiaHe Rd, Xiamen,China |
| 전화번호: |
+86-592-5881089 |
| 팩스번호:
|
+86-592-5854960 |
| E - mail: |
xie@china-sinoway.com |
|
현재위치
: Home > Trade 
